YOLFTbeta
00

Harbin Gloria Pharmaceuticals

002437 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

2.93CNY-0.11 (-3.62%)

Price History

Full chart

Market Stats

Previous Close3.04
Open3.04
Day Range2.91 – 3.05
52-Week Range2.37 – 5.10
Volume140.55M
Market Cap8.07B
P/E (TTM)20.11
Forward P/E64.94
EPS0.18
Dividend Yield0.00%
Beta0.17
50-Day Avg3.67
200-Day Avg3.35

About

HARBIN GLORIA PHARMACEUTICALS Co., LTD, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China and internationally. The company offers cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamin supplements, electrolyte drugs, hypoglycemic drugs, analgesics, digestive system and metabolic drugs, anti-infective drugs, and anti-tumor drugs. It also provides deer antler polypeptide injections, Annao pills and tablets, potassium chloride sustained-release tablets, sodium creatine phosphate for injection, ginkgo biloba extract injections, vitamins (B12), fluorouracil for injection, bleomycin hydrochloride for injection, and other injectable products, as well as pravastatin sodium tablets, olmesartan medoxomil amlodipine tablets, and edoxaban tosylate tablets. In addition, the company engages in pharmaceutical promotion; project investment; investment services; trade import and export; wholesale and retail; and technology promotion and application services. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is headquartered in Harbin, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Leifeng Guo
  • Employees2.35K
  • HeadquartersNo. 29, Beijing Road, Harbin, China, 150025, China
  • Websitehttps://www.gloria.cc

Leadership

  • Mr. Leifeng GuoGM, CFO & Director · b. 1973
  • Mr. Kang ZhouDeputy GM & Non-Independent Director · b. 1984
  • Ms. Yueyin LiuDeputy GM, Non-Independent Director & Secretary of the Board · b. 1986
  • Mr. Xiaohang WangDeputy General Manager · b. 1979
  • Mr. Runbao LiDeputy General Manager · b. 1968
  • Ms. Xiaojing ZhouAccounting Supervisor · b. 1985

Financials

Income Statement

Currency: CNY2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue164.11M275.61M429.93M575.45M546.36M711.03M1.31B1.91B2.68B2.98B3.04B5.48B5.05B3.05B3.15B3.11B2.63B2.44B2.14B
Growth (%)-+67.94%+55.99%+33.85%-5.05%+30.14%+83.94%+45.72%+40.69%+11.28%+1.95%+80.20%-7.80%-39.55%+2.96%-1.19%-15.51%-7.06%-12.51%
Cost of Revenue56.36M99.71M187.32M269.23M280.64M258.55M298.93M705.89M990.46M1.24B898.54M1.40B1.34B850.49M832.93M1.36B1.10B1.14B1.17B
Gross Profit107.75M175.90M242.61M306.22M265.72M452.48M1.01B1.20B1.69B1.74B2.14B4.08B3.71B2.20B2.31B1.75B1.53B1.30B968.37M
Gross Margin65.66%63.82%56.43%53.21%48.63%63.64%77.14%62.96%63.06%58.46%70.46%74.43%73.43%72.16%73.52%56.17%58.27%53.40%45.35%
Operating Expense30.47M67.17M90.87M125.01M127.09M295.42M807.57M708.78M928.46M969.01M1.80B3.91B6.18B1.63B2.22B2.02B1.36B1.02B699.59M
Operating Income77.28M108.73M151.74M181.21M138.63M157.06M201.40M491.15M762.31M775.27M342.86M172.06M-2.47B579.12M95.89M-270.09M175.05M284.85M268.78M
Operating Margin47.09%39.45%35.29%31.49%25.37%22.09%15.40%25.77%28.43%25.98%11.27%3.14%-48.92%18.96%3.05%-8.69%6.67%11.67%12.59%
EBITDA80.43M121.82M168.05M205.19M157.81M225.50M349.44M667.72M1.06B1.12B717.42M519.52M-2.27B806.76M296.42M-58.57M323.01M397.29M502.89M
EBITDA Margin49.01%44.20%39.09%35.66%28.88%31.71%26.72%35.04%39.43%37.67%23.58%9.48%-44.91%26.41%9.42%-1.88%12.30%16.28%23.55%
Net Income74.76M105.95M130.24M154.71M116.85M164.77M226.74M443.77M664.81M716.65M309.68M125.89M-2.66B400.05M45.04M-291.33M120.33M232.76M376.91M
Net Income Margin45.55%38.44%30.29%26.89%21.39%23.17%17.34%23.28%24.79%24.02%10.18%2.30%-52.67%13.10%1.43%-9.37%4.58%9.54%17.65%
R&D---436.16K19.74M35.44M71.63M77.98M106.84M114.26M91.95M136.88M185.79M130.51M101.77M98.68M85.44M75.34M78.43M
R&D as % of Total Revenue---0.08%3.61%4.98%5.48%4.09%3.98%3.83%3.02%2.50%3.68%4.27%3.24%3.17%3.25%3.09%3.67%
Interest Expense1.64M3.29M3.26M3.69M77.98K82.48K416.13K27.73M88.30M111.21M170.21M174.83M153.09M92.48M84.65M81.07M42.65M10.02M2.48M
Interest Expense % of Total Revenue1.00%1.19%0.76%0.64%0.01%0.01%0.03%1.45%3.29%3.73%5.60%3.19%3.03%3.03%2.69%2.61%1.62%0.41%0.12%

Balance Sheet

Currency: CNY2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets215.51M279.21M442.48M2.19B2.31B2.56B2.94B4.92B8.32B8.67B9.06B9.48B6.41B4.52B4.70B4.07B3.15B2.83B3.13B
Total Liabilities77.15M85.17M154.95M73.73M114.91M203.79M464.60M1.82B4.85B4.62B4.81B5.08B4.82B2.58B2.72B2.37B1.44B852.26M825.00M
Total Equity138.30M194.04M287.53M2.12B2.17B2.33B2.39B3.02B3.40B3.96B4.17B4.32B1.52B1.85B1.89B1.63B1.66B1.95B2.29B
Cash41.40M42.29M87.97M1.54B1.45B1.26B829.92M1.07B1.19B1.20B961.79M1.31B1.31B895.45M1.50B1.24B711.28M481.96M396.40M
Total Debt36.07M52.00M92.00M-30.00M25.00M-950.99M3.62B3.72B3.57B3.12B2.68B1.35B1.56B1.45B675.69M1.95M-
Net Debt-5.33M9.71M4.03M-1.54B-1.42B-1.24B-829.92M-120.16M2.42B2.52B2.61B1.81B1.37B457.00M62.42M217.23M-35.59M-480.02M-

Cash Flow

Currency: CNY2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow52.26M57.81M170.82M112.59M128.61M205.89M453.02M674.04M702.05M1.04B651.80M1.16B610.37M12.76M274.18M261.62M274.18M410.94M273.36M
Investing Cash Flow-27.67M-17.97M-124.52M-240.88M-180.09M-433.73M-708.00M-1.49B-1.65B-1.52B-1.45B-167.35M70.83M1.01B81.26M-223.88M94.38M-58.86M-
Financing Cash Flow-16.58M-38.96M-616.19K1.58B-35.32M39.02M-177.80M1.05B901.88M425.29M521.11M-782.20M-263.95M-1.66B361.59M-212.55M-889.16M-583.24M-
Capital Expenditure13.17M38.08M61.47M240.88M166.90M144.37M163.35M125.89M283.10M185.34M194.63M104.34M48.43M43.66M34.51M33.01M29.62M62.90M23.81M
Free Cash Flow39.09M19.73M109.34M-128.29M-38.30M61.52M289.67M548.14M418.95M855.14M457.16M1.06B561.94M-30.90M239.67M228.60M244.55M348.04M249.54M
Dividends Paid5.88M53.34M40.01M3.69M70.00M2.12M168.36M59.48M154.66M254.93M263.85M186.63M26.38M134.48M70.94M68.76M43.81M9.36M1.21M
FCF to OCF74.79%34.14%64.01%-113.94%-29.78%29.88%63.94%81.32%59.68%82.19%70.14%91.03%92.07%-242.08%87.41%87.38%89.20%84.69%91.29%
Dividend Paid to FCF15.05%270.32%36.59%-2.88%-182.78%3.44%58.12%10.85%36.92%29.81%57.72%17.63%4.69%-435.23%29.60%30.08%17.91%2.69%0.48%

Earnings

Report DateAug 23, 2014Oct 26, 2014Feb 13, 2015Apr 25, 2015Aug 25, 2015Oct 26, 2015Feb 2, 2016Apr 27, 2016Aug 28, 2016Oct 21, 2016Apr 21, 2017Aug 25, 2017Oct 27, 2017Feb 28, 2018Apr 25, 2018Aug 3, 2018Oct 25, 2018Apr 23, 2019Aug 28, 2019Oct 28, 2019Apr 28, 2020Aug 28, 2020Oct 28, 2020Apr 29, 2021Aug 27, 2021Oct 29, 2021Apr 26, 2022Aug 29, 2022Oct 27, 2022Apr 24, 2023Jul 29, 2023Oct 27, 2023May 10, 2024Aug 24, 2024Oct 29, 2024Apr 24, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate---0.040.08-0.090.06--0.08-0.09-0.060.07-------------------------
EPS Actual0.060.050.070.050.090.080.110.060.090.100.070.040.030.01-0.010.050.04-0.090.070.04-1.350.00-0.010.010.04-0.000.000.010.000.010.000.09-0.050.030.030.020.030.050.060.040.03
Surprise---25.00%12.50%-22.22%0.00%---12.50%--66.67%--116.67%-28.57%-------------------------
TimingPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursPre-marketAfter-hoursPre-market--------Pre-market-----After-hours--------

Key Statistics & Ratios

Market Cap8.07B
Enterprise Value7.18B
Trailing P/E20.11
Forward P/E64.94
PEG Ratio0.00
Price / Sales3.95
Price / Book3.28
EPS0.18
Book Value1.11
Revenue (TTM)2.04B
Gross Profit (TTM)913.71M
EBITDA332.57M
Profit Margin19.65%
Operating Margin16.71%
Return on Equity17.87%
Return on Assets4.97%
Shares Outstanding2.23B
Shares Float1.93B
Beta0.17
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20191×
0.01Jun 28, 2019
20181×
0.01Jul 18, 2018
20171×
0.05Jun 13, 2017
20161×
0.08Jun 3, 2016
20151×
0.03May 8, 2015
20141×
0.01Jul 4, 2014
20131×
0.08May 28, 2013
20111×
0.03Mar 29, 2011

Stock Splits

  • Jun 3, 201630:10
  • Sep 19, 201425:10